A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Imaprelimab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Prothena
- 03 May 2018 Status changed from recruiting to completed.
- 28 Sep 2017 Results presented in a Prothena Media Release.
- 08 Aug 2017 According to a Prothena media release, top-line results from this trial are expected in October 2017.